BlackRock’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-5,666,347
| Closed | -$137M | – | 5698 |
|
|
2023
Q1 | $137M | Buy |
5,666,347
+86,743
| +2% | +$1.09M | ﹤0.01% | 1823 |
|
|
2022
Q4 | $59M | Buy |
5,579,604
+549,256
| +11% | +$4.43M | ﹤0.01% | 2351 |
|
|
2022
Q3 | $22.6M | Buy |
5,030,348
+424,311
| +9% | +$1.93M | ﹤0.01% | 2968 |
|
|
2022
Q2 | $18.4M | Buy |
4,606,037
+214,287
| +5% | +$1.02M | ﹤0.01% | 3130 |
|
|
2022
Q1 | $32.1M | Sell |
4,391,750
-92,175
| -2% | -$551K | ﹤0.01% | 2864 |
|
|
2021
Q4 | $25.2M | Sell |
4,483,925
-6,801
| -0.2% | -$43.2K | ﹤0.01% | 3140 |
|
|
2021
Q3 | $28.7M | Sell |
4,490,726
-56,421
| -1% | -$363K | ﹤0.01% | 3045 |
|
|
2021
Q2 | $38.3M | Buy |
4,547,147
+84,038
| +2% | +$678K | ﹤0.01% | 2867 |
|
|
2021
Q1 | $46.8M | Buy |
4,463,109
+537,620
| +14% | +$7.57M | ﹤0.01% | 2660 |
|
|
2020
Q4 | $66.5M | Buy |
3,925,489
+611,338
| +18% | +$9.16M | ﹤0.01% | 2303 |
|
|
2020
Q3 | $42.5M | Buy |
3,314,151
+428,534
| +15% | +$5.41M | ﹤0.01% | 2396 |
|
|
2020
Q2 | $40.7M | Buy |
2,885,617
+2,203,387
| +323% | +$27.8M | ﹤0.01% | 2381 |
|
|
2020
Q1 | $6.28M | Buy |
682,230
+25,299
| +4% | +$326K | ﹤0.01% | 3240 |
|
|
2019
Q4 | $9.79M | Buy |
656,931
+173,917
| +36% | +$1.55M | ﹤0.01% | 3255 |
|
|
2019
Q3 | $3.3M | Buy |
483,014
+157,323
| +48% | +$1.59M | ﹤0.01% | 3602 |
|
|
2019
Q2 | $3.94M | Buy |
325,691
+301,052
| +1,222% | +$1.64M | ﹤0.01% | 3590 |
|
|
2019
Q1 | $57K | Sell |
24,639
-1,596
| -6% | -$3.75K | ﹤0.01% | 4463 |
|
|
2018
Q4 | $46K | Buy |
26,235
+5,472
| +26% | +$15.7K | ﹤0.01% | 4490 |
|
|
2018
Q3 | $84K | Buy |
+20,763
| New | +$82.1K | ﹤0.01% | 4480 |
|
Other funds holding PRVB
BlackRock's PRVB Position: Q2 2023 in Review
BlackRock sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 5,666,347 shares — an estimated $137M sold.
BlackRock first reported a position in PRVB in Q3 2018 and held it in 19 quarters. The position peaked at $137M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- BlackRock reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- BlackRock sold 5,666,347 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $137M.
- BlackRock first reported a position in Provention Bio, Inc. Common Stock in Q3 2018 and held it in 19 quarters.
- BlackRock's Provention Bio, Inc. Common Stock position peaked at $137M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on BlackRock's 13F filing for Q2 2023, filed 11 Aug 2023.